195 related articles for article (PubMed ID: 24264883)
1. Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria.
Krajewski KM; Nishino M; Franchetti Y; Ramaiya NH; Van den Abbeele AD; Choueiri TK
Cancer; 2014 Mar; 120(5):711-21. PubMed ID: 24264883
[TBL] [Abstract][Full Text] [Related]
2. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
[TBL] [Abstract][Full Text] [Related]
3. 10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study.
Krajewski KM; Franchetti Y; Nishino M; Fay AP; Ramaiya N; Van den Abbeele AD; Choueiri TK
Oncologist; 2014 May; 19(5):507-14. PubMed ID: 24755461
[TBL] [Abstract][Full Text] [Related]
4. Vascular Tumor Burden as a New Quantitative CT Biomarker for Predicting Metastatic RCC Response to Antiangiogenic Therapy.
Smith AD; Zhang X; Bryan J; Souza F; Roda M; Sirous R; Zhang H; Vasanji A; Griswold M
Radiology; 2016 Nov; 281(2):484-498. PubMed ID: 27603788
[TBL] [Abstract][Full Text] [Related]
5. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
AJR Am J Roentgenol; 2010 Jun; 194(6):1470-8. PubMed ID: 20489085
[TBL] [Abstract][Full Text] [Related]
6. Thymic measurements in pathologically proven normal thymus and thymic hyperplasia: intraobserver and interobserver variabilities.
Araki T; Sholl LM; Gerbaudo VH; Hatabu H; Nishino M
Acad Radiol; 2014 Jun; 21(6):733-42. PubMed ID: 24809315
[TBL] [Abstract][Full Text] [Related]
7. CT Intensity Distribution Curve (Histogram) Analysis of Patients Undergoing Antiangiogenic Therapy for Metastatic Renal Cell Carcinoma.
Boos J; Revah G; Brook OR; Rangaswamy B; Bhatt RS; Brook A; Raptopoulos V
AJR Am J Roentgenol; 2017 Aug; 209(2):W85-W92. PubMed ID: 28570097
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of clinical outcomes of antiangiogenic-targeted therapy in patients with pulmonary metastatic renal cell carcinoma using non-contrast-enhanced computed tomography.
Wu GY; Suo ST; Kong W; Jin D; Zhang J; Xu JR
Acad Radiol; 2014 Nov; 21(11):1434-40. PubMed ID: 25097010
[TBL] [Abstract][Full Text] [Related]
9. CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool.
Nishino M; Guo M; Jackman DM; DiPiro PJ; Yap JT; Ho TK; Hatabu H; Jänne PA; Van den Abbeele AD; Johnson BE
Acad Radiol; 2011 Jan; 18(1):54-62. PubMed ID: 21036632
[TBL] [Abstract][Full Text] [Related]
10. Interobserver and intraobserver variability of RECIST assessment in ovarian cancer.
Krasovitsky M; Lee YC; Sim HW; Chawla T; Moore H; Moses D; Baker L; Mandel C; Kielar A; Hartery A; O'Malley M; Friedlander M; Oza AM; Wang L; Lheureux S; Wilson M
Int J Gynecol Cancer; 2022 May; 32(5):656-661. PubMed ID: 35379690
[TBL] [Abstract][Full Text] [Related]
11. Metastatic renal cell carcinoma: radiologic findings and assessment of response to targeted antiangiogenic therapy by using multidetector CT.
Brufau BP; Cerqueda CS; Villalba LB; Izquierdo RS; González BM; Molina CN
Radiographics; 2013 Oct; 33(6):1691-716. PubMed ID: 24108558
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy.
Han KS; Jung DC; Choi HJ; Jeong MS; Cho KS; Joung JY; Seo HK; Lee KH; Chung J
Cancer; 2010 May; 116(10):2332-42. PubMed ID: 20225226
[TBL] [Abstract][Full Text] [Related]
13. Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy.
Williams R; Hudson JM; Lloyd BA; Sureshkumar AR; Lueck G; Milot L; Atri M; Bjarnason GA; Burns PN
Radiology; 2011 Aug; 260(2):581-90. PubMed ID: 21555352
[TBL] [Abstract][Full Text] [Related]
14. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.
Smith AD; Lieber ML; Shah SN
AJR Am J Roentgenol; 2010 Jan; 194(1):157-65. PubMed ID: 20028918
[TBL] [Abstract][Full Text] [Related]
15. RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Krajewski KM; Nishino M; Ramaiya NH; Choueiri TK
AJR Am J Roentgenol; 2015 Mar; 204(3):W282-8. PubMed ID: 25714313
[TBL] [Abstract][Full Text] [Related]
16. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib.
Thiam R; Fournier LS; Trinquart L; Medioni J; Chatellier G; Balvay D; Escudier B; Dromain C; Cuenod CA; Oudard S
Ann Oncol; 2010 May; 21(5):936-41. PubMed ID: 19889607
[TBL] [Abstract][Full Text] [Related]
17. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response.
Erasmus JJ; Gladish GW; Broemeling L; Sabloff BS; Truong MT; Herbst RS; Munden RF
J Clin Oncol; 2003 Jul; 21(13):2574-82. PubMed ID: 12829678
[TBL] [Abstract][Full Text] [Related]
18. Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.
Kang HC; Gupta S; Wei W; Lu L; Matrana MR; Tannir NM; Choi H
AJR Am J Roentgenol; 2017 Dec; 209(6):1278-1284. PubMed ID: 29064751
[TBL] [Abstract][Full Text] [Related]
19. Intra- and interobserver variability in CT measurements in oncology.
McErlean A; Panicek DM; Zabor EC; Moskowitz CS; Bitar R; Motzer RJ; Hricak H; Ginsberg MS
Radiology; 2013 Nov; 269(2):451-9. PubMed ID: 23824993
[TBL] [Abstract][Full Text] [Related]
20. Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria.
Suzuki C; Torkzad MR; Jacobsson H; Aström G; Sundin A; Hatschek T; Fujii H; Blomqvist L
Acta Oncol; 2010 May; 49(4):509-14. PubMed ID: 20397778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
